1. Potential new therapeutic target for Alzheimer's disease: Glucagon‐like peptide‐1
- Author
-
Ping Xu, Ni Zhang, Xiao-Yu Liu, and Sheng-Xiao Zhang
- Subjects
endocrine system ,endocrine system diseases ,business.industry ,General Neuroscience ,digestive, oral, and skin physiology ,nutritional and metabolic diseases ,Type 2 Diabetes Mellitus ,Disease ,Bioinformatics ,Neuroprotection ,Glucagon-like peptide-1 ,Mini review ,Diabetes Mellitus, Type 2 ,Incretin Hormone ,Alzheimer Disease ,Glucagon-Like Peptide 1 ,Close relationship ,Humans ,Medicine ,Cognitive Dysfunction ,Cognitive impairment ,business ,hormones, hormone substitutes, and hormone antagonists - Abstract
Increasing evidence shows a close relationship between Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM). Recently, glucagon-like peptide-1 (GLP-1), a gut incretin hormone, has become a well-established treatment for T2DM and is likely to be involved in treating cognitive impairment. In this mini review, the similarities between AD and T2DM are summarised with the main focus on GLP-1-based therapeutics in AD.
- Published
- 2021